ReShape Lifesciences jumps after modified obesity device gets FDA nod

Vyome Holdings

13/12/2023 11:01

** Metabolic health solutions firm ReShape Lifesciences
shares  RSLS.O  rise 47% to $0.37 premarket - among biggest pct
gainers across U.S. stock exchange 
    ** RSLS said on Tuesday the U.S. health regulator has
granted approval to supplemental co's pre-market application for
a modified version of its device to treat obesity
    ** The modified version uses newer technology which allows
for larger pieces of food to pass through the narrow passage
created by the use of the silicone device
    ** The GLP-1 agonists can be used to complement and augment
weight loss after surgery to help prevent weight regain - RSLS
    ** GLP-1 agonists were originally designed to treat type 2
diabetes and have been shown to reduce food cravings and cause
the stomach to empty more slowly
    ** Up to Tuesday's close, stock had fallen ~96% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))